Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Sterility, Stability, and Efficacy of Repackaged Anti-VEGF Agents for Intravitreal Administration
TCTR20240924004Completed
- Sponsor
- Mahidol University
- Start
- Apr 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of bevacizumab, aflibercept, ranibizumab, brolucizumab and faricimab in exudative macular degeneration, diabetic macular edema (DME), Vein occlusion (RVO) and 1 more, sponsored by Mahidol University. Primary endpoints: Sterility of repackaged anti-VEGF syringes, Physicochemical stability after repackaging and 1 more. Started Apr 2024; status: completed.
02
Drugs
bevacizumabafliberceptranibizumabbrolucizumabfaricimab
03
Conditions
exudative macular degenerationdiabetic macular edema (DME)Vein occlusion (RVO)retinal vascular disease
Beyond the preview
Go deeper on TCTR20240924004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240924004.